1. Liu, Yanfeng, Tao, Shishi, Liao, Lijuan, Yang, Xiaolu, Chen, Liang. 2020. TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway. In Nature communications, 11, 348. doi:10.1038/s41467-019-14190-2. https://pubmed.ncbi.nlm.nih.gov/31953436/
2. Gack, Michaela U, Shin, Young C, Joo, Chul-Hyun, Inoue, Satoshi, Jung, Jae U. . TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. In Nature, 446, 916-920. doi:. https://pubmed.ncbi.nlm.nih.gov/17392790/
3. Zheng, Bowen, Qian, Fengyuan, Wang, Xuehui, Zhou, Baian, Fang, Lin. 2024. Neddylation activated TRIM25 desensitizes triple-negative breast cancer to paclitaxel via TFEB-mediated autophagy. In Journal of experimental & clinical cancer research : CR, 43, 177. doi:10.1186/s13046-024-03085-w. https://pubmed.ncbi.nlm.nih.gov/38926803/
4. Chen, Yike, Xu, Xiaohui, Ding, Kaikai, Ji, Jianxiong, Zhang, Jianmin. 2024. TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1/c-MYC pathway by targeting the splicing factor NONO. In Journal of experimental & clinical cancer research : CR, 43, 39. doi:10.1186/s13046-024-02964-6. https://pubmed.ncbi.nlm.nih.gov/38303029/
5. Choudhury, Nila Roy, Heikel, Gregory, Michlewski, Gracjan. 2020. TRIM25 and its emerging RNA-binding roles in antiviral defense. In Wiley interdisciplinary reviews. RNA, 11, e1588. doi:10.1002/wrna.1588. https://pubmed.ncbi.nlm.nih.gov/31990130/